{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T05:48:37Z","timestamp":1709272117853},"reference-count":99,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.beha.2004.08.013","type":"journal-article","created":{"date-parts":[[2004,10,21]],"date-time":"2004-10-21T11:29:22Z","timestamp":1098358162000},"page":"623-639","source":"Crossref","is-referenced-by-count":4,"title":["Modulation of angiogenesis in patients with myelodysplastic syndrome"],"prefix":"10.1016","volume":"17","author":[{"given":"Elihu H.","family":"Estey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2004.08.013_bib1","first-page":"609","article-title":"Low-dose melphalan for treatment of high-risk myelodysplastic syndromes","volume":"10","author":"Omoto","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2004.08.013_bib2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0145-2126(02)00028-0","article-title":"Treatment of myelodysplastic syndromes with 5-azacytidine","volume":"26","author":"Gryn","year":"2002","journal-title":"Leukemia Research"},{"key":"10.1016\/j.beha.2004.08.013_bib3","first-page":"51a","article-title":"Phase II study of amifostine in patients with myelodysplastic syndromes (MDS)","volume":"18","author":"List","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2004.08.013_bib4","first-page":"3364","article-title":"Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome","volume":"90","author":"List","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1089\/jir.1998.18.871","article-title":"Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes","volume":"18","author":"Reza","year":"1998","journal-title":"Journal of the Interferon & Cytokine Research"},{"key":"10.1016\/j.beha.2004.08.013_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0093-7754(01)90287-8","article-title":"Overview of angiogenesis: biologic implications for antiangiogenic therapy","volume":"28","author":"Ellis","year":"2001","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.beha.2004.08.013_bib7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/10454411950060030501","article-title":"The pathophysiology of angiogenesis","volume":"6","author":"Polverini","year":"1995","journal-title":"Critical Reviews in Oral Biology and Medicine"},{"key":"10.1016\/j.beha.2004.08.013_bib8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1126\/science.2432664","article-title":"Angiogenic factors","volume":"235","author":"Folkman","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.beha.2004.08.013_bib9","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/sj.leu.2402220","article-title":"Prognostic evaluation of the microvascular network in myelodysplastic syndromes","volume":"15","author":"Korkolopoulou","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2004.08.013_bib10","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.bjc.6693515","article-title":"Angiogenesis in myelodysplastic syndromes","volume":"81","author":"Pruneri","year":"1999","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.beha.2004.08.013_bib11","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/cncr.10900","article-title":"Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes","volume":"95","author":"Aguayo","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2004.08.013_bib12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000046613","article-title":"Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome","volume":"106","author":"Albitar","year":"2001","journal-title":"Acta Haematologica"},{"key":"10.1016\/j.beha.2004.08.013_bib13","first-page":"2240","article-title":"Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes","volume":"96","author":"Aguayo","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/152581602753448586","article-title":"Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia","volume":"11","author":"Brunner","year":"2002","journal-title":"Journal of Hematothereapy & Stem Cell Research"},{"key":"10.1016\/j.beha.2004.08.013_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0145-2126(98)00175-1","article-title":"Low plasma stem cell factor levels correlate with in vitro leukemic growth in myelodysplastic syndromes","volume":"23","author":"Cortelezzi","year":"1999","journal-title":"Leukemia Research"},{"key":"10.1016\/j.beha.2004.08.013_bib16","first-page":"194","article-title":"Proliferation and differentiation of myelodysplastic CD34+ cells: phenotypic subpopulations of marrow CD34+ cells","volume":"85","author":"Sawada","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib17","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.beha.2004.08.013_bib18","first-page":"1029","article-title":"Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis","volume":"146","author":"Dvorak","year":"1995","journal-title":"American Journal of Pathology"},{"key":"10.1016\/j.beha.2004.08.013_bib19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/0955-0674(95)80116-2","article-title":"Proteolytic remodeling of extracellular matrix","volume":"7","author":"Birkedal-Hansen","year":"1995","journal-title":"Current Opinion in Cell Biology"},{"key":"10.1016\/j.beha.2004.08.013_bib20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/376062a0","article-title":"Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice","volume":"376","author":"Shalaby","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.beha.2004.08.013_bib21","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1126\/science.285.5433.1553","article-title":"KDR receptor: a key marker defining hematopoietic stem cells","volume":"285","author":"Ziegler","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.beha.2004.08.013_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/370555a0","article-title":"Processing of tumour necrosis factor-alpha precursor by metalloproteinases","volume":"370","author":"Gearing","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.beha.2004.08.013_bib23","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/blood.V97.5.1427","article-title":"Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes","volume":"97","author":"Bellamy","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0925-5710(95)00412-2","article-title":"Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor","volume":"62","author":"Broxmeyer","year":"1995","journal-title":"International Journal of Hematology"},{"key":"10.1016\/j.beha.2004.08.013_bib25","first-page":"4150","article-title":"Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo","volume":"92","author":"Gabrilovich","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib26","first-page":"2844","article-title":"Roles for integrin very late activation antigen-4 in stroma-dependent erythropoiesis","volume":"83","author":"Yanai","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib27","first-page":"138","article-title":"Specific domains of fibronectin mediate adhesion and migration of early murine erythroid progenitors","volume":"90","author":"Goltry","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib28","first-page":"3263","article-title":"Growth-supporting activities of fibronectin on hematopoietic stem\/progenitor cells in vitro and in vivo: structural requirement for fibronectin activities of CS1 and cell-binding domains","volume":"91","author":"Yokota","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib29","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0955-0674(96)80116-5","article-title":"Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface","volume":"8","author":"Basbaum","year":"1996","journal-title":"Current Opinion on Cell Biology"},{"key":"10.1016\/j.beha.2004.08.013_bib30","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","article-title":"A metalloproteinase disintegrin that releases tumour-necrosis factor- alpha from cells","volume":"385","author":"Black","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.beha.2004.08.013_bib31","first-page":"61","article-title":"Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia","volume":"26","author":"List","year":"1999","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.beha.2004.08.013_bib32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2141.1999.01352.x","article-title":"Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells","volume":"105","author":"Janowska-Wieczorek","year":"1999","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2004.08.013_bib33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1084\/jem.180.1.95","article-title":"Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice","volume":"180","author":"Xu","year":"1994","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.beha.2004.08.013_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/10428199709058305","article-title":"Regulation of hematopoiesis by microvascular endothelium","volume":"27","author":"Rafii","year":"1997","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2004.08.013_bib35","first-page":"3230","article-title":"The effect of alpha4 beta1-integrin binding sequences of fibronectin on growth of cells from human hematopoietic progenitors","volume":"91","author":"Schofield","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib36","first-page":"846","article-title":"Opposing effects of engagement of integrins and stimulation of cytokine receptors on cell cycle progression of normal human hematopoietic progenitors","volume":"95","author":"Jiang","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1084\/jem.174.3.693","article-title":"Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin","volume":"174","author":"Verfaillie","year":"1991","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.beha.2004.08.013_bib38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1172\/JCI118063","article-title":"Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation","volume":"96","author":"Hurley","year":"1995","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.beha.2004.08.013_bib39","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1023\/A:1011141009812","article-title":"Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers","volume":"12","author":"Bertolini","year":"2001","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.beha.2004.08.013_bib40","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1046\/j.1365-2141.2001.02921.x","article-title":"Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome","volume":"114","author":"Verstovsek","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2004.08.013_bib41","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/10428190109064609","article-title":"High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome","volume":"42","author":"Verstovsek","year":"2001","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2004.08.013_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cncr.10200","article-title":"Clinical significance of plasma endostatin in acute myeloid leukemia\/myelodysplastic syndrome","volume":"94","author":"Lai","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2004.08.013_bib43","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/sj.leu.2402586","article-title":"Correlation of bone marrow angiogenesis and mast cells with tryptase activity in myelodysplastic syndromes","volume":"16","author":"Ribatti","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2004.08.013_bib44","first-page":"376a","article-title":"Involvement of inhibitor of apoptosis protein Survivin in patients with myelodysplastic syndromes","volume":"100","author":"Cai","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood.V98.1.241","article-title":"Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia","volume":"98","author":"Mesters","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib46","first-page":"99","article-title":"SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types","volume":"59","author":"Fong","year":"1999","journal-title":"Cancer Research"},{"key":"10.1016\/j.beha.2004.08.013_bib47","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V97.5.1413","article-title":"The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts","volume":"97","author":"Smolich","year":"2001","journal-title":"Blood"},{"issue":"supplement 5","key":"10.1016\/j.beha.2004.08.013_bib48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1634\/theoncologist.6-suppl_5-32","article-title":"The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies","volume":"6","author":"Giles","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.beha.2004.08.013_bib49","first-page":"2798","article-title":"Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies","volume":"8","author":"Stopeck","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beha.2004.08.013_bib50","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2002-10-3023","article-title":"SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes","volume":"102","author":"Giles","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib51","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1517\/14712598.3.2.263","article-title":"VEGF blocking therapy in the treatment of cancer","volume":"3","author":"Glade-Bender","year":"2003","journal-title":"Experimental Opinion on Biological Therapy"},{"key":"10.1016\/j.beha.2004.08.013_bib52","first-page":"337a","article-title":"Phase I trial of PTK787\/ZK 222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases in acute myeloid leukemia and myelodysplastic syndrome","volume":"100","author":"Roboz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib53","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/jnci\/94.19.1484","article-title":"Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies","volume":"94","author":"Jayson","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.beha.2004.08.013_bib54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/sonc.2002.37264","article-title":"Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications","volume":"29","author":"Ferrara","year":"2002","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.beha.2004.08.013_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2002.37265","article-title":"Tumor angiogenesis and accessibility: role of vascular endothelial growth factor","volume":"29","author":"Jain","year":"2002","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.beha.2004.08.013_bib56","first-page":"9a","article-title":"Successful long-term therapy with bevacizumab (Avastin) in solid tumors","volume":"21","author":"Langmuir","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2004.08.013_bib57","first-page":"206","article-title":"The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: The Eastern Cooperative Oncology Group's (ECOG) experience with bevacizumab (anti-VEGF)","volume":"22","author":"Gray","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2004.08.013_bib58","first-page":"243","article-title":"Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200","volume":"22","author":"Benson","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2004.08.013_bib59","first-page":"19","article-title":"Clinical development of anti-angiogenic agents in 2002","volume":"90","author":"Bachelot","year":"2003","journal-title":"Bulletin du Cancer"},{"key":"10.1016\/j.beha.2004.08.013_bib60","first-page":"36","article-title":"Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers","volume":"9","author":"Rosen","year":"2002","journal-title":"Cancer Control"},{"key":"10.1016\/j.beha.2004.08.013_bib61","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.beha.2004.08.013_bib62","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.beha.2004.08.013_bib63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0162-3109(95)00050-X","article-title":"Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade","volume":"31","author":"Geitz","year":"1996","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.beha.2004.08.013_bib64","first-page":"375a","article-title":"Thalidomide significantly modifies bone marrow microenvironment in myelodysplastic syndrome (MDS) patients","volume":"100","author":"Alvi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib65","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","article-title":"Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib66","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2141.2001.03204.x","article-title":"The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes","volume":"115","author":"Zorat","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2004.08.013_bib67","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.11180","article-title":"A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome","volume":"97","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2004.08.013_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2402330","article-title":"Thalidomide for the treatment of patients with myelodysplastic syndromes","volume":"16","author":"Strupp","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2004.08.013_bib69","first-page":"622a","article-title":"Thalidomide (THAL) significantly improves anemia in selected transfusion-dependent patients with Myelodysplastic syndromes (MDS): Relationship to serum and marrow levels of angiogenetic growth factors (AGF)","volume":"98","author":"Musto","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib70","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","article-title":"Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects","volume":"87","author":"Dredge","year":"2002","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.beha.2004.08.013_bib71","first-page":"2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib72","first-page":"593","article-title":"A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins","volume":"63","author":"Marriott","year":"2003","journal-title":"Cancer Research"},{"key":"10.1016\/j.beha.2004.08.013_bib73","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00001622-200211000-00008","article-title":"Thalidomide and immunomodulatory drugs as cancer therapy","volume":"14","author":"Raje","year":"2002","journal-title":"Current Opinion in Oncology"},{"key":"10.1016\/j.beha.2004.08.013_bib74","first-page":"790a","article-title":"Trisenox (Arsenic trioxide, ATO) in patients (pts) with myelodysplastic syndromes (MDS): preliminary findings in a phase II clinical study","volume":"100","author":"List","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib75","first-page":"795a","article-title":"Trilineage responses to Arsenic trioxide (Trisenox\u00ae) and thalidomide in patients with myelodysplastic syndromes (MDS), particularly those with inv(3)(q21q26.2)","volume":"100","author":"Raza","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib76","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2002-05-1459","article-title":"High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients","volume":"101","author":"Barjesteh van","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib77","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0037-1963(01)90126-X","article-title":"Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies","volume":"38","author":"Karp","year":"2001","journal-title":"Seminars in Hematology"},{"key":"10.1016\/j.beha.2004.08.013_bib78","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/00001813-200209000-00016","article-title":"Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April","volume":"13","author":"Caponigro","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.beha.2004.08.013_bib79","first-page":"927","article-title":"Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer","volume":"18","author":"Zujewski","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2004.08.013_bib80","first-page":"4947","article-title":"Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice","volume":"58","author":"Liu","year":"1998","journal-title":"Cancer Research"},{"key":"10.1016\/j.beha.2004.08.013_bib81","first-page":"848a","article-title":"Phase II study of R115777, a farnesyltransferse inhibitor, in myelodysplastic syndrome","volume":"98","author":"Kurzrock","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib82","first-page":"623a","article-title":"Phase I study of a farnesyltransferase inhibitor R115777, in patients with myelodysplastic syndrome","volume":"98","author":"Kurzrock","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib83","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/shem.2002.36925","article-title":"Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome","volume":"39","author":"Kurzrock","year":"2002","journal-title":"Seminars in Hematology"},{"key":"10.1016\/j.beha.2004.08.013_bib84","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/shem.2002.35986","article-title":"Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies","volume":"39","author":"Kantarjian","year":"2002","journal-title":"Seminars in Hematology"},{"key":"10.1016\/j.beha.2004.08.013_bib85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/shem.2002.35984","article-title":"Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies","volume":"39","author":"Cortes","year":"2002","journal-title":"Seminars in Hematology"},{"key":"10.1016\/j.beha.2004.08.013_bib86","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1517\/13543784.10.12.2105","article-title":"Farnesyltransferase inhibitors: mechanism and applications","volume":"10","author":"Prendergast","year":"2001","journal-title":"Experimental Opinion on Investigation Drugs"},{"key":"10.1016\/j.beha.2004.08.013_bib87","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3816\/CBC.2003.n.005","article-title":"Inhibiting ras signaling in the therapy of breast cancer","volume":"3","author":"Li","year":"2003","journal-title":"Clinical Breast Cancer"},{"key":"10.1016\/j.beha.2004.08.013_bib88","first-page":"789a","article-title":"Phase I study of continuous oral administration of Lonafarnib (Sarasar\u2122) in patients with advanced hematologic malignancies","volume":"100","author":"List","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib89","first-page":"793a","article-title":"Continuous oral Lonafarnib (Sarasar) for the treatment of patients with advanced hematological malignancies: A phase II Study","volume":"100","author":"Cortes","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib90","first-page":"794a","article-title":"Phase I-II study of a farnesyl transferase inhibitor (FTI) SCH66336, in patients with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML)","volume":"100","author":"Ravoet","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib91","first-page":"1065","article-title":"A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer","volume":"8","author":"Hahn","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beha.2004.08.013_bib92","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/1042819021000040387","article-title":"The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro","volume":"44","author":"Huang","year":"2003","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2004.08.013_bib93","doi-asserted-by":"crossref","first-page":"16464","DOI":"10.1074\/jbc.M112274200","article-title":"Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1","volume":"277","author":"Hanai","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.beha.2004.08.013_bib94","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2002.11.061","article-title":"Phase I study of recombinant human endostatin in patients with advanced solid tumors","volume":"20","author":"Herbst","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2004.08.013_bib95","first-page":"789a","article-title":"Randomized, double-blind Phase II study of the matrix metalloprotease (MMP) inhibitor, AG3340 (Prinomastat\u2122) in patients with Myelodysplastic syndrome (MDS)","volume":"100","author":"List","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.08.013_bib96","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1046\/j.1365-2141.2001.02722.x","article-title":"Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor","volume":"113","author":"de Bont","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2004.08.013_bib97","first-page":"52","article-title":"Bone marrow stromal cell distribution of basic fibroblast growth factor in chronic myeloid disorders","volume":"86","author":"Yoon","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2004.08.013_bib98","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0145-2126(02)00268-0","article-title":"Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia","volume":"27","author":"Chou","year":"2003","journal-title":"Leukemia Research"},{"key":"10.1016\/j.beha.2004.08.013_bib99","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1046\/j.1365-2141.2003.04289.x","article-title":"Expression of cox-2, tie-2 and glycodelin by megakaryocytes in patients with chronic myeloid leukaemia and polycythaemia vera","volume":"121","author":"Zetterberg","year":"2003","journal-title":"British Journal of Haematology"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1521692604000799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1521692604000799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T06:56:50Z","timestamp":1497596210000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692604000799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":99,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S1521692604000799"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2004.08.013","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}